Actively Recruiting
Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response
Led by Ömer Faruk Okumuş · Updated on 2025-12-03
104
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.
CONDITIONS
Official Title
Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent.
- Systemically healthy without diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions affecting periodontal status.
- Have at least 20 natural teeth, excluding third molars.
- No antibiotic therapy or periodontal treatment in the last 6 months.
- For healthy controls: No clinical attachment loss, probing depth ≤ 3 mm, no bone loss on X-rays, and low gum and plaque scores.
- For mild periodontitis: Diagnosed with Stage I or II periodontitis, clinical attachment loss 1-4 mm, bone loss 15-33%, and non-smoker.
- For severe periodontitis: Diagnosed with Stage III or IV periodontitis, clinical attachment loss ≥ 5 mm, advanced bone loss, and non-smoker.
- For severe periodontitis with smoking: Same as severe periodontitis plus regular smoking of at least 10 cigarettes daily for 5 years or more.
You will not qualify if you...
- Fewer than 20 natural teeth, excluding third molars.
- Presence of systemic diseases such as diabetes, immune disorders, or cancer.
- Use of antibiotics or periodontal treatment in the last 6 months.
- Pregnancy or breastfeeding.
- For healthy controls: Any signs of periodontitis.
- For periodontitis groups: History of quitting smoking for at least 5 years; must be current smoker or never smoker as defined by group.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erzincan Binali Yıldırım University Faculty of Dentistry
Erzincan, Erzincan, Turkey (Türkiye), 24002
Actively Recruiting
Research Team
Ö
Ömer F. Okumuş, DDS,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here